Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Safety of lacto-N-fucopentaose I/2'-fucosyllactose (LNFP-I/2'-FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283

EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) et al. EFSA J. .

Abstract

Following a request from the European Commission, the EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA) was asked to deliver an opinion on lacto-N-fucopentaose I (LNFP-I)/2'-fucosyllactose (2'-FL) mixture as a novel food (NF) pursuant to Regulation (EU) 2015/2283. The NF is mainly composed of the human-identical milk oligosaccharides (HiMO) LNFP-I and 2'-FL, but it also contains d-lactose, lacto-N-tetraose, difucosyllactose, 3-fucosyllactose, LNFP-I fructose isomer, 2'-fucosyl-d-lactulose, l-fucose and 2'-fucosyl-d-lactitol, and a small fraction of other related saccharides. The NF is produced by fermentation by a genetically modified strain (Escherichia coli K-12 DH1 MDO MP2173b) of E. coli K-12 DH1 (DSM 4235). The information provided on the identity, manufacturing process, composition and specifications of the NF does not raise safety concerns. The applicant intends to add the NF in a variety of foods, including infant formula (IF) and follow-on formula, foods for infants and toddlers, foods for special medical purposes and food supplements (FS). The target population is the general population. The anticipated daily intake of LNFP-I from use in IF is similar to the estimated natural mean highest daily intake in breastfed infants. Overall, the anticipated daily intake of LNFP-I from the NF as a food ingredient at the maximum proposed use levels is unlikely to exceed the intake level of breastfed infants on a body weight basis. The intake in breastfed infants on a body weight basis is expected to be safe also for other population groups. The anticipated 2'-FL intake is generally rather low. The use of the NF in FS is not intended if other foods with added NF components or human milk (for infants and young children) are consumed on the same day. The Panel concludes that the NF, a mixture of LNFP-I and 2'-FL, is safe under the proposed conditions of use.

Keywords: 2’‐FL; 2′‐fucosyllactose; HiMO; LNFP‐I; human milk oligosaccharide; lacto‐N‐fucopentaose I; novel food.

PubMed Disclaimer

Conflict of interest statement

If you wish to access the declaration of interests of any expert contributing to an EFSA scientific assessment, please contact interestmanagement@efsa.europa.eu.

Figures

FIGURE 1
FIGURE 1
Chemical structure of LNFP‐I (top) and 2’‐FL (bottom).
See this image and copyright information in PMC

References

    1. Aldredge, D. L. , Geronimo, M. R. , Hua, S. , Nwosu, C. C. , Lebrilla, C. B. , & Barile, D. (2013). Annotation and structural elucidation of bovine milk oligosaccharides and determination of novel fucosylated structures. Glycobiology, 23, 664–676. - PMC - PubMed
    1. Austin, S. , De Castro, C. A. , Sprenger, N. , Binia, A. , Affolter, M. , Garcia‐Rodenas, C. L. , Beauport, L. , Tolsa, J. F. , & Fischer Fumeaux, C. J. (2019). Human milk oligosaccharides in the milk of mothers delivering term versus preterm infants. Nutrients, 11, 1282. - PMC - PubMed
    1. Blattner, F. R. , Plunkett, G., III , Bloch, C. A. , Perna, N. T. , Burland, V. , Riley, M. , Collado‐Vides, J. , Glasner, J. D. , Rode, C. K. , Mayhew, G. F. , Gregor, J. , Davis, N. W. , Kirkpatrick, H. A. , Goeden, M. A. , Rose, D. J. , Mau, B. , & Shao, Y. (1997). The complete genome sequence of Escherichia coli K‐12. Science, 277, 1453–1462. - PubMed
    1. Bode, L. (2012). Human milk oligosaccharides: Every baby needs a sugar mama. Glycobiology, 22, 1147–1162. - PMC - PubMed
    1. Breg, J. , Romijn, D. , Vliegenthart, J. F. G. , Strecker, G. , & Monteuil, J. (1988). Scope and limitations of rotating‐frame nuclear overhauser enhancements spectroscopy applied to oligosaccharides. Carbohydrate Research, 183, 19–34. - PubMed

LinkOut - more resources